Roche’s GA101 Met Goals in Stage One of Trial to Replace Rituxan
This article is for subscribers only.
Roche Holding AG said a next-generation blood cancer drug met its target in the first stage of a trial that could help the treatment replace top-seller Rituxan in patients with chronic lymphocytic leukemia.
GA101 combined with chemotherapy helped CLL patients live longer without their disease progressing than chemotherapy alone, the Basel, Switzerland-based drugmaker said in an e-mailed statement today. The medicine is a partnership with U.S. biotechnology company Biogen Idec Inc.